Articles tagged with Cell Therapies
Researchers at Brigham and Women's Hospital have designed a probiotic to suppress autoimmunity in the brain, which is at the core of several diseases including MS. The treatment offers a more precise way to target brain inflammation with reduced negative side effects compared to standard therapies.
Researchers explore CDK9 inhibitors as a promising combination partner in treating hematological malignancies. They discuss the role of cyclin-dependent kinases (CDKs) in these diseases and highlight the potential synergism with other drugs.
Researchers developed innovative techniques to treat challenging cancers and manage therapy side effects. Inhibitors targeting PRMT5, a histone-modifying enzyme, alleviated cisplatin-induced hearing loss, while nano-pills delivered combination drugs to liver cancer cells.
Researchers highlight the need for effective treatment strategies for adenoid cystic carcinoma (ACC) of the head and neck, which is a highly malignant tumor with variable localizations. Proton therapy shows decisive advantages in long-term survival rates for ACC.
Researchers successfully deployed CAR-T therapy in a mouse model of ovarian cancer, demonstrating strong anti-tumor effects even at late stages. The treatment was highly effective, shrinking or eliminating tumors after just one dose and continuing to work for months without major side effects.
Researchers have identified a novel therapeutic target for pelvic pain in endometriosis by focusing on the IL-1β pathway and its regulation via the JNK signaling pathway. This study suggests that JNK inhibitors may be effective in reducing neuroinflammation and alleviating symptoms of endometriosis-associated pain.
Researchers investigated H3K27me3 expression patterns in pediatric brain tumors, finding a global loss of this epigenetic mark in diffused midline glioma (DMG). This loss was associated with high relapse rates and poor survival, highlighting the potential for targeting H3K27me3 as an epigenetically guided cancer therapy.
A team of researchers at the University of Oklahoma has made a groundbreaking discovery in overcoming antimicrobial resistance by developing a new class of molecules that inhibit efflux pumps. These inhibitors work as 'molecular wedges' targeting the area between bacterial cell membranes, increasing the effectiveness of antibiotics.
Targeting tiny amounts of hydrogen sulfide to specific areas of cells in adult worms improved health and activity as they aged, according to a University of Exeter study. The research found that H2S improved the integrity of mitochondria, kept muscles active, and extended lifespan.
A new review paper suggests scrambler therapy can yield significant relief for approximately 80-90% of patients with chronic pain. The therapy works by capturing nerve endings and replacing pain signals with signals from adjacent areas, 'scrambling' the pain signals sent to the brain.
Researchers found that Alzheimer's patients exhibit heightened sensitivity to light changes, which can contribute to 'sundowning' and disease progression. Light therapy could help manage these symptoms and potentially slow disease progression.
Researchers have identified KIAA0930 as a key factor causing muscle atrophy in cancer cells, which could lead to the development of new anti-cachexia therapies. The study found that KIAA0930 knockdown cells showed increased muscle mass and weight compared to control cells.
Researchers at Sahmyook University repurposed meclofenamate to treat abnormal respiratory mucus, reducing mucin secretion and characteristics of respiratory mucus. This study offers an alternative solution for patients with respiratory diseases, saving time and costs compared to conventional drug development strategies.
Researchers at UCL and Stanford University create a three-component anti-cancer therapy using click chemistry, improving cancer-killing efficiency with sialidase enzyme, and exploring potential for next-generation agents.
Dr. Beau Webber received a two-year Translation to CURE award to study genetically engineered gamma delta T cells for treating metastatic osteosarcoma. This innovative approach aims to address the limitations of current immune-cell based therapies and offers new hope for childhood cancer treatment.
Researchers propose targeting non-canonical HH/GLI signaling to improve response rate and durability of therapeutic effects exerted by SMO inhibition in melanoma. The findings suggest that combined targeting of hedgehog signaling and BRD4 could provide a novel therapeutic option against melanoma.
Researchers found that BUB1 protein regulates EGFR signaling by reducing receptor internalization, which may lead to new therapeutic interventions for EGFR-driven cancers. The study also showed that BUB1 impacts receptor recycling and degradation, affecting signaling amplitude and duration.
Researchers have discovered a way to identify pregnant women at risk of preeclampsia by examining lipids in their blood during pregnancy. The approach worked regardless of whether the women were on aspirin therapy, and could predict the risk of preeclampsia with significant accuracy.
A novel biomaterials-based approach enhances adoptive T cell therapy with cancer vaccine technology, providing strong and long-lasting effects against solid tumors. In mice carrying melanomas, SIVET enables fast tumor shrinking and long-term protection.
A new study found that cetuximab plus radiotherapy is an active treatment option for locally advanced cutaneous squamous cell skin cancer, with an objective response rate of 83.2%. The treatment was well-tolerated, with most patients experiencing mild acneiform skin rash or fatigue.
Mass General Cancer Center researchers have pinpointed the APOBEC3A protein as a primary driver of drug resistance in non-small-cell lung cancer. The study reveals that this protein causes mutations and accelerates tumor growth, making it a promising target for new therapies.
Mass General Brigham researchers have made key improvements to Parkinson's disease cell therapies by using regulatory T cells to supplement neuronal cell therapy. The study shows that co-transplanting regulatory T cells with dopaminergic neurons increases survival and improves behavior recovery in rodent models.
A new study reveals that preoperative hydroxyprogesterone administration can improve disease-free and overall survival in patients with node-positive breast cancer by modulating cellular stress response and negative regulation of inflammation. Non-coding RNAs, such as DSCAM-AS1, play a regulatory role in this process.
Researchers at St. Jude Children's Research Hospital created a more accurate hepatoblastoma model to improve therapies, focusing on DNA damage repair pathways. The model identified potential targets and validated the effectiveness of PRKDC inhibition when combined with doxorubicin, enhancing treatment efficacy.
Researchers at Nagoya University have discovered three new biomarkers for high-grade serous ovarian carcinoma using membrane proteins and polyketone-coated nanowires. The study reveals that small extracellular vesicles containing these proteins can be used to detect ovarian cancer, potentially leading to personalized medicine.
Researchers discovered that Nerofe and Doxorubicin can downregulate KRAS signaling, leading to enhanced apoptosis in colorectal cancer cells. The combination also activates the immune system against tumor cells, increasing immunostimulatory cytokines and recruiting NK cells and M1 macrophages.
A team from the University of Ottawa has developed a comprehensive screening platform and cellular interrogation tool to facilitate novel drug discovery targeting various human diseases. The 'Tango-Trio' platform can identify small molecule modulators for orphan GPCRs, which have significant untapped therapeutic potential.
St. Jude researchers found that supplying glutamine to tumors enhances the immune system's cancer-killing activity, while a molecular pathway identified as a potential drug target could improve anti-cancer therapies. Glutamine helps activate dendritic cells, which then activate T cells that kill cancer cells.
A new study describes an engineered approach that makes protein aggregates amenable to spatial manipulations in both budding yeast and human cells. This system allows for the export of protein aggregates from cells, potentially protecting mother cells from toxicity and contributing to a better understanding of neurodegenerative diseases.
A research team from HKUMed has developed a new platform to rapidly engineer and select the best precise genome editors for therapeutic applications. The platform allows for parallel testing of hundreds of base editor variants, enabling the selection of the most suitable ones with maximal efficiency and minimal undesired edits.
Researchers investigated premature senescence in biliary atresia and assessed senotherapies. They found that human allogenic liver-derived progenitor cells reduced early markers of senescence and improved liver disease in a preclinical model, providing encouraging results for pediatric biliary cirrhosis treatment.
Three University Hospitals and Case Western Reserve University research teams received $50,000 Collaborative Science Pilot Awards to explore innovative research projects. The awards aim to increase competitiveness and capacity for major external funding opportunities in key areas such as cancer, brain health and genetics.
Researchers are exploring natural killer cells as a potential treatment for neuropathic pain, which is caused by nerve damage. NK cells may help prune damaged nerve cells, providing relief from chronic pain.
Researchers at MD Anderson Cancer Center have engineered a new model of aggressive renal cell carcinoma, highlighting molecular targets and genomic events that trigger chromosomal instability. The loss of interferon receptor genes plays a pivotal role in allowing cancer cells to become tolerant of chromosomal instability.
Cartesian Therapeutics has successfully treated patients with generalized myasthenia gravis using an RNA CAR-T therapy. The trial demonstrated marked and long-lasting clinical improvement, with three patients achieving complete or near-complete eradication of disease symptoms.
Peruvoside has been discovered to prevent up to 12 medically important viruses, including SARS-CoV-2, Hand, Foot and Mouth Disease (HFMD), and Influenza. The compound acts on GBF1 protein, disabling its functionality and stopping virus production.
A small-scale clinical trial suggests a modified CAR-T therapy could effectively reduce myasthenia gravis symptoms, with three patients showing complete elimination of symptoms. The treatment was well-tolerated and has the potential for longer-lasting results compared to current treatments.
Recent studies in the New Journal of Pharmaceutical Analysis feature novel diagnostic tools, RNA sequencing-based workflows, and mechanical property evaluations to enhance cancer and cardiovascular disease treatment outcomes. These innovations aim to improve the therapeutic effect of drugs and promote personalized medicine.
Researchers have identified anti-malarial properties in cancer drugs, offering a potential solution to the growing crisis of drug-resistant malaria. The study found that certain protein kinase inhibitors exhibited strong anti-malarial effects, highlighting a new approach to accelerating drug discovery.
Researchers developed Precious1GPT, a multimodal transformer-based approach for aging clock development and feature importance analysis. The model utilizes methylation and transcriptomic data to predict biological age and identify disease-related genes, providing a pathway for therapeutic drug discovery.
Researchers found a link between short telomeres in ATII cells and lung fibrosis in post-COVID-19 patients. The study revealed loss of ATII cellularity and shorter telomeres concomitant with increased fibrotic lung parenchyma remodeling.
UCF researcher Dr. Justine Tigno-Aranjuez has discovered a new receptor that recognizes house dust mite allergens, opening up potential for broad-spectrum therapy. The finding could lead to improved treatments for common allergies, including asthma.
Researchers at UCL have developed base-edited T-cells that can fight leukemia, showing promise in a NHS clinical trial. Three patients with relapsed T-cell leukaemia were treated with the cells, with one patient experiencing complete remission after just four weeks.
Researchers have identified LP-284 as a novel acylfulvene compound with anti-tumor activity against non-Hodgkin's lymphoma. The compound exerts nanomolar potency in 15 NHL cell lines and prolongs survival of mantle cell lymphoma xenograft mice, making it a potential therapeutic option for patients with HR or TC-NER deficiency.
Scientists from Institut Pasteur and Inserm discovered that CD4 T cells can remotely neutralize tumor cells by producing interferon gamma, offering new hopes for patients with incomplete responses to CAR T cell therapy. This study raises the possibility of personalized treatment approaches using larger quantities of CD4 CAR T cells.
Researchers at the University of Pennsylvania School of Engineering and Applied Science have developed a new therapy that uses engineered macrophages to eliminate solid tumors. The treatment works by silencing a molecular pathway that prevents white blood cells from attacking cancer cells, allowing them to recognize and destroy tumoroids.
Researchers found that blocking histamine-releasing factor (HRF) and immunoglobulin E (IgE) interactions may provide relief for patients with severe asthma. The study, published in The Journal of Allergy and Clinical Immunology, suggests two potential therapies, including HRF-2CA and a therapeutic antibody called SPF7-1.
A study has identified a potential treatment target for prostate cancer that is resistant to hormone therapy, a protein modification involving TRAF4. The researchers found that TRAF4 promotes the spread of cancer and may be associated with a new treatment option for patients.
Indiana University School of Medicine researchers will investigate muscle-directed gene therapies and test alternative treatment options for degenerative disorders like Duchenne muscular dystrophy. The goal is to develop more successful and long-term ways to help patients living with muscle disorders.
Researchers at UCLA have developed a new method to bioprint miniature tumor organoids that can mimic the function and architecture of real tumors. This allows for the accurate measurement of individual organoids, enabling the identification of personalized treatments for people with rare or hard-to-treat cancers.
A study published in JAMA Oncology suggests that stopping immunotherapy after two years for patients with advanced non–small cell lung cancer who remain responsive may be a reasonable strategy, providing sustained clinical benefit. The findings provide reassurance for patients and their healthcare providers.
Researchers developed a method to 'tip the balance' of immune cells from bad to good, reversing MS-like symptoms in 100% of mice and achieving full recovery in 38%. The therapy uses biodegradable microparticles to deliver three key therapeutic agents, including rapamycin and a myelin peptide.
An observational study of 329,000 Medicare admissions found that older persons receiving hospital care from allopathic (M.D.) or osteopathic (D.O.) physicians experience similar quality and cost of care. Researchers also highlight systemic health inequities faced by persons with sickle cell disease.
Researchers discuss chemotherapeutic resistance in recurring ovarian cancer, focusing on the unfolded protein response and its effect on polyploid giant cancer cells. Understanding this mechanism could lead to investigating cancer cell molecular mechanisms and potential therapeutic strategies.
Researchers have discovered that HER3 plays a crucial role in promoting cell survival in metastatic colorectal and pancreatic cancer. The surrounding liver microenvironment activates HER3, making it an emerging therapeutic target for these types of cancer.
Researchers discovered that FDA-approved HDAC-inhibitors can impact energy metabolism in solid tumor cells, including glioblastoma. The combination of HDAC-inhibitors and imipridones may synergize to enhance killing of GBM cells by reversing cellular respiration.
Researchers at UCLA Jonsson Comprehensive Cancer Center have found a potential therapeutic target, IL-21, to reduce endocrine autoimmune side effects from checkpoint immunotherapy. A specific group of immune cells play a central role in this autoimmune attack and blocking IL-21 prevents thyroid autoimmunity.
Researchers developed predictive models to design RNA-binding inhibitors for disease treatment by regulating protein production. The study identified three key features for effective oligonucleotides: thermostability, serum resistance, and RNase H sensitivity.
Scientists have engineered plants to produce peptides with antibiotic activity against drug-resistant pathogens, which also enhances stability and prolongs activity. The resulting plants yield potent drugs at significantly lower costs than traditional methods, making them an environmentally friendly option for pharmaceutical production.
Researchers used cancer proteomics data to identify gene candidates for therapeutic targeting, focusing on protein kinases in uterine endometrial cancer cells. Public molecular resources and multi-omics data analysis can prioritize genes of interest for future studies.